Skip to Content
Morningstar
Get 14 Days Free

Eli Lilly and Co LLY

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Eli Lilly Posts Strong Q4 as Pipeline Advancements Support Robust Long-Term Growth Outlook

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Eli Lilly reported strong fourth-quarter results slightly ahead of our earnings projection, but we don’t expect any major fair value estimate changes based on the minor outperformance. The strong operating results help complement one of the strongest developing drug pipelines in the industry, reinforcing our wide moat rating.

Read Full Analysis

Company Profile

Business Description

Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Contact
Lilly Corporate Center
Indianapolis, IN, 46285
T +1 317 276-2000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Classic Growth
Employees 19,500

Related

Market Update
These Sectors Performed Best and Worst in the Pandemic
We look at the industries for those most affected by social-distancing and stay-at-home orders.
Sachin Nagarajan
Stock Strategist Industry Reports
COVID-19 Sales Have No Major Impact on Drug and Vaccine Manufacturers We Cover
However, the biopharma industry's ability to adapt and innovate to treat disease reinforces our moat ratings.
Karen Andersen
Stock Strategist Industry Reports
Biopharma Companies With COVID-19 Treatments See $10 Billion Market in 2021
We expect quickly declining sales potential after that, however.
Damien Conover
Stock Analyst Update
Eli Lilly Provides Strong Outlook and Positive Updates
The wide-moat firm continues to show significant innovation. We plan to increase our fair value estimate.
Damien Conover
Stock Strategist Industry Reports
Implementation of Trump's Drug-Pricing Orders Unlikely
We don't foresee any impact on pharma companies' moats or valuations.
Damien Conover
Stock Strategist Industry Reports
We Still Expect a Strong U.S. Economic Recovery
Neither the U.S. election outcome nor the coronavirus third wave will derail it.
Preston Caldwell
Stock Strategist Industry Reports
Slow Burn Likely Until Coronavirus Vaccines Are Widely Available
Resurgences in outbreaks make it clear that ending the pandemic will require more than diagnostic testing, contact tracing, and social distancing.
Karen Andersen
Stock Strategist Industry Reports
Innovation Supports Growth at Big Pharma/Big Biotech Companies
Moats and returns on invested capital look stable for companies with a solid list of pipeline drugs.
Damien Conover
Stock Analyst Update
Drug Pricing Executive Orders Not Likely to Affect FVEs
We don’t expect these actions by President Trump to significantly affect our fair value estimates or moat ratings due to limited details, challenging implementation, and only minor impacts.
Damien Conover
Stock Strategist Industry Reports
Timeline Accelerates for COVID-19 Drug Development
Three new vaccines for coronavirus look poised for emergency use authorization in the U.S. this fall.
Karen Andersen
Stock Strategist
Positive Data Boosts Outlook for Lilly
The wide-moat drugmaker's growth prospects are improving.
Damien Conover
Stock Strategist Industry Reports
Coronavirus Vaccine Progress Accelerates
Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.
Karen Andersen
Stock Strategist Industry Reports
Coronavirus Has Limited Impact on Big Pharma and Big Biotech
Moats, valuations, and dividends look attractive in the market pullback.
Damien Conover
Stock Analyst Update
Recent Drug Launches Support Strong Quarter for Lilly
We have raised our fair value estimate based on an improving outlook.
Damien Conover
Commentary
The Week Ahead: Earnings Heat Up With Apple, Amazon, and Facebook
Reports are also due for Visa, Exxon, Verizon, and many more.
Jess Liu
Stock Strategist Industry Reports
How ESG Risk Affects Pharma and Biotech Moats and Valuations
Morningstar and Sustainalytics offer complementary methodologies.
Karen Andersen
Investing Specialists
Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks
We find several actionable ideas that yield more than the S&P 500.
The Morningstar Ultimate Stock-Pickers Team
Advisor Insights
Big Pharma, Wide Moats
Innovation and M&A may drive these firms' fortunes.
Laura Lallos
US Videos
Acquisitions Targets Among Drugmakers
We think the market underappreciates some large pharma and biotech names.
Karen Andersen
Stock Strategist
Incyte's Undervalued as Pipeline Progresses
A broad array of oncology and autoimmune programs gives the company a larger margin of error.
Karen Andersen